"Designing Growth Strategies is in our DNA"

U.S. Dry Eye Syndrome Market Size, Share & COVID-19 Impact Analysis, By Product (Anti-inflammatory Products {Cyclosporin, Corticosteroids, and Others}, Artificial Tears and Lubricants, and Others) By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, and Others), and Forecast, 2023-2030

Region : USA | Format: PDF | Report ID: FBI107538

 

KEY MARKET INSIGHTS

Play Audio Listen to Audio Version

The U.S. dry eye syndrome market size was valued at USD 2.84 billion in 2022. The market is projected to grow from USD 3.02 billion in 2023 to USD 4.86 billion by 2030, exhibiting a CAGR of 7.0% during the forecast period.


Dry Eye Syndrome (DES) is one of the most commonly observed clinical diseases in the U.S. The subjective symptoms of this condition include irritation, dryness, eye fatigue, foreign body sensation, pain, heavy sensation, brightness, discharge, and fluctuating visual disturbances. It has been observed that this condition is becoming more prevalent amongst the aging population suffering from chronic conditions such as diabetes. As per a study published by Springer Nature in June 2022, there are 16 million confirmed Dry Eye Syndrome (DES) diagnoses in the U.S., and another 6 million people have the symptoms but have not been diagnosed yet. This rise in the prevalence of this condition amongst the geriatric population will lead to an increase in the adoption of these products for treatment.


The public and private organizations of the U.S. are focusing on increasing awareness among the general population by initiating events and campaigns and celebrating July as National Dry Eye Awareness Month. Moreover, even the market players are promoting their product offerings by introducing innovative campaigns to educate patients about the treatment options for this condition. A stronger need for better ocular health, in conjunction with increased awareness for eye care products, is expected to contribute to the U.S. dry eye syndrome market growth during the forecast period.


COVID-19 IMPACT


U.S. Market Witnessed a Negative Impact due to Decrease in the Diagnosis Rate


The U.S. healthcare system has witnessed a negative impact due to the novel coronavirus. The reason for the market decline included lockdown restrictions that were imposed across various states in the U.S. during the initial days of the pandemic to curb the spread of the novel coronavirus. During the pandemic, several factors contributed to the increase in the patient pool of this disease due to the long term exposure to blue lights of electronic gadgets for work or study purposes, which caused strains on the eye led to dry eye syndrome. However, the U.S. market witnessed a decline due to decrease in the adoption of therapeutic measures, owing to COVID-19 lockdown restrictions. This led to disruptions in supply chains and demand for these products.



  • As per a 2020 study published by the Ocular Surface, among 388 respondents, 25% had mild, 21% had moderate, and 54% had severe dry eye. The study was conducted on people working from home during the pandemic.


However, the market players witnessed a steady growth in the revenue of their product in the post pandemic and this growth continued in the FY 2022 too.



  • Restasis, a product of Allergan, a company of AbbVie, Inc., generated revenues of USD 755.0 million, USD 1,234.0 million, and USD 621.0 million in FY 2020, FY 2021, and FY 2022, respectively in the U.S. market. Similarly, the Refresh series of the company also exhibited positive growth in the period of FY 2020-2022.


Such positive growth exhibited by the key players in this market will continue throughout the forecast period.


LATEST TRENDS


Request a Free sample to learn more about this report.


Strong Pipeline is expected to Create Market Growth Potential


One of the key trends is that the market players are making strategic alliances to support and accelerate the development of pipeline candidates. The introduction of these pipeline candidates in the market will expand the treatment options for patients suffering from this condition. Therefore, companies are investing largely in upscaling their research & development activities to establish their presence and drive market growth in the forecast period.



  • For instance, ReGenTree is a U.S. joint venture between HLB Therapeutics and RegeneRx Biopharmaceuticals, Inc., specifically to develop RGN-259 in both the U.S. and Canada for ophthalmic indications. ReGenTree licensed the rights to RGN-259 from RegeneRx in 2015. Thus far, ReGenTree has sponsored three Phase 3 studies in the U.S. for dry eye, which are ARISE-1 (Phase 2b/3), ARISE-2, and ARISE-3. These emergent trends are expected to contribute strongly to the growth in the forecast period.


DRIVING FACTORS


Increasing Prevalence of Dry Eye Disease to Aid Market Growth 


One of the major drivers responsible for market growth is the increasing prevalence of this condition in the U.S. An increase in the prevalence of this condition will expand the patient pool, which will surge the demand for effective therapeutic measures, leading to market growth. According to the Dry Eye Directory Statistics of 2022, between 16 million and 49 million Americans have dry eyes. The rise in prevalence rates of this condition will contribute to an increase in the adoption of effective treatment options.


Moreover, patients suffering from medical conditions, such as Sjogren's syndrome, allergic eye disease, rheumatoid arthritis, lupus, scleroderma, graft vs. host disease, sarcoidosis, thyroid disorders, or vitamin A deficiency, are at high risk of getting this condition. Hence, this will further increase the diagnosis rate of this disease and the number of patients opting for its treatment, which offer growth opportunities in the forecast period.



  • In 2021, a survey was conducted by the Sjögren’s Foundation, Inc., in which it was observed that out of 3,622 respondents suffering from Sjögren’s syndrome, 95% had dry eye symptoms. Such driving factors are expected to further boost the adoption of these products in the forecast period.


Awareness Initiative by Market Players to Drive the Market Growth


Government and non-government initiatives are encouraging many individuals to seek diagnoses and treatment for this condition. In July 2021, the Alliance for Eye and Vision Research (AEVR) along with the Tear Film & Ocular Surface Society (TFOS) hosted the sixth annual Dry Eye Awareness Month Congressional Briefing. The aim of the event was to discuss the causes and quality of life impacts from dry eye disease.


Furthermore, many companies involved in this market promote their products through effective strategies, ultimately contributing to the growth trajectory. This is particularly relevant as factors, such as rising awareness of better ocular health and greater efficiency of treatment outcomes, are expected to drive the market’s growth in the forecast period.



  • In July 2020, Novartis launched its direct-to-consumer commercial campaigns named Not Today, Dry Eye, which aims at improving awareness regarding dry eye disease among consumers. The growing awareness about available treatment options and the increased need for improved ocular health are anticipated to boost market growth.


RESTRAINING FACTORS


High Costs of Approved Products to Limit Market Growth


Another critical factor that is limiting the growth of the global market is the high cost of products associated with the treatment of this condition.



  • For instance, RESTASIS (Cyclosporine Ophthalmic Emulsion) 0.05% is a higher priced drug product involved in multiple controversies regarding price and patent protection. Further increases in the cost of this product will negatively influence the purchasing nature of the patient population in terms of getting treatment for this condition.


Moreover, companies are focusing on getting regulatory approvals for generic versions of branded products such as Restasis. Hence, such factors are expected to hinder the growth of the market in the forthcoming years.


SEGMENTATION


By Product Analysis


To know how our report can help streamline your business, Speak to Analyst


Anti-inflammatory Segment to Dominate Market in 2022 Due to Increasing Adoption


By product, the market is segmented into anti-inflammatory, artificial tears and lubricants, and others.


The anti-inflammatory segment held a major market share in 2022. The growth of the segment is attributed to the rising demand for prescription medications such as anti-inflammatory drugs. As per an article published by the Journal of Clinical Medicine in 2022, in the U.S., the principle approach for the treatment of this condition is anti-inflammatory therapy. These drugs being the main line of treatment options in the country will increase their adoption rate, leading to segmental growth.


The artificial tears and lubricants held the second largest U.S. dry eye syndrome market share in 2022, owing to the continuous launches of over-the-counter lubricants for the condition, which is projected to drive the segment’s growth. In July 2021, Bausch + Lomb, a leading global eye health business of Bausch Health Companies Inc., launched the Biotrue Hydration Boost Lubricating Eye Drops in the U.S. that are indicated to relieve symptoms associated with irritated, dry eyes. Such launches will help the segment expand in the U.S. market.


The others segment is estimated to grow at the highest CAGR and includes pipeline candidates and nasal sprays such as Tyrvaya (varenicline solution).


By Distribution Channel Analysis


Large Patient Population Seeking Treatment in Hospitals will Lead to Segment’s Dominance in 2022


By distribution channel, the market is segmented is classified into hospital pharmacies, retail pharmacies, online pharmacies, and others.


The hospital pharmacies segment accounted for the highest market share in 2022. This segment's dominance is largely attributable to the presence of a large patient population seeking treatment for this condition in hospitals, which increases the demand for such drugs in hospital pharmacies.


The retail pharmacies held the second largest share in 2022 and the segment’s growth is attributed to the use of these settings for the procurement of prescription refills. Online pharmacies are expected to grow at the highest CAGR during the forecast period due to factors such as better pricing for artificial tears and lubricants. Moreover, online pharmacies make medications easier to access and more convenient than at retail and hospital pharmacies, which is expected to drive the segment’s growth. Others segment is estimated to grow at a comparatively lower CAGR during the forecast period.


KEY INDUSTRY PLAYERS


Strong Product Portfolio of AbbVie to Intensify its Market Presence in 2022


In terms of the competitive landscape, AbbVie, Inc. has established its market presence through its strong product offering the Over-The-Counter (OTC) products in the artificial tears and lubricants segment. Refresh series is one of the leading product ranges in the market, which is contributing to the company’s established market presence. Similarly, Alcon is focusing on increasing its market share by making strategic acquisitions of products, such as Eysuvis, which is indicated to treat this syndrome.


Some of the other companies with a considerable presence in the U.S. market include Novartis AG. For instance, in May 2019, Novartis AG acquired Takeda’s Xiidra, the first and only prescription treatment approved for both signs and symptoms of dry eye disease. Such strategic moves are expected to further enable companies to strengthen their market presence. Other companies, such as Sun Pharmaceuticals Industries, Inc., Otsuka Pharmaceutical Co., Ltd., Johnson & Johnson Vision Care, Inc., and Santen Pharmaceuticals, are focusing on upscaling their R&D initiatives to introduce novel products in the market.


LIST OF KEY COMPANIES PROFILED:



KEY INDUSTRY DEVELOPMENTS:



  • November 2022: Alcon acquired Aerie Pharmaceuticals Inc. to expand its ophthalmic pharmaceutical product portfolio. Alcon has also acquired a pipeline of potential ophthalmic pharmaceutical product candidates to make use of Aerie's current research & development resources.

  • February 2022: Mylan Pharmaceuticals Inc. received approval from the U.S. FDA for the generic version of AbbVie’s Restasis drug that is indicated to increase tear production in patients with dry eye syndrome.

  • November 2021: I-MED Pharma Inc. announced to launch Its Innovative Dry Eye Product Portfolio in the U.S., giving dry eye patients long-lasting relief.

  • January 2021: Kala Pharmaceuticals, Inc. received approval for Eysuvis from the U.S. FDA as the first and only corticosteroid indicated to treat the signs and symptoms of dry eye disease for up to two weeks.

  • October 2019: Sun Pharmaceuticals Industries Ltd. launched the ophthalmic solution Cequa in the U.S. market, which is indicated for treating dry eye disease.


REPORT COVERAGE


To gain extensive insights into the market, Request for Customization


The research report includes a robust research methodology and provides a detailed analysis and focuses on key aspects such as prevalence of dry eye syndrome in the U.S., key industry developments, pipeline analysis, new product launches, reimbursement policies, regulatory scenario, overview of novel approaches to treat dry eyes, key industry trend, healthcare industry overview, impact of COVID-19 on the market, and overview of over-the-counter eye lubricants in the market. Besides this, the report also offers insights into the market trends and highlights key industry dynamics. In addition to the aforementioned factors, it encompasses several factors that have contributed to the growth of the market in recent years.


Report Scope & Segmentation


















































  ATTRIBUTE



  DETAILS



Study Period



2019-2030



Base Year



2022



Estimated Year



2023



Forecast Period



2023-2030



Historical Period



2019-2021



Growth Rate



CAGR of 7.0% from 2023 to 2030



Unit



Value (USD billion)



Segmentation



By Product and Distribution Channel



By Product




  • Anti-inflammatory Products

    • Cyclosporin

    • Corticosteroids

    • Others



  • Artificial Tears and Lubricants

  • Others



By Distribution Channel




  • Hospital Pharmacies

  • Retail Pharmacies

  • Online Pharmacies

  • Others






Frequently Asked Questions

Fortune Business Insights says that the market size was USD 2.84 billion in 2022 and is projected to reach USD 4.86 billion by 2030.

In 2022, the market stood at USD 2.84 billion.

Registering a CAGR of 7.0%, the market will exhibit steady growth during the forecast period (2023-2030).

The anti-inflammatory segment is expected to lead this market during the forecast period.

The increasing demand for anti-inflammatory drugs with a focus on getting regulatory approvals is a major factor driving the growth of the market.

AbbVie, Inc. is the major player in this market.

The rising prevalence of dry eye syndrome among the geriatric population coupled with long screen time is expected to drive the adoption.

Seeking Comprehensive Intelligence on Different Markets?
Get in Touch with Our Experts

Speak to an Expert
  • May, 2023
  • 2022
  • 2019-2021
  • 100

Personalize this Research

  • Granular Research on Specified Regions or Segments
  • Companies Profiled based on User Requirement
  • Broader Insights Pertaining to a Specific Segment or Region
  • Breaking Down Competitive Landscape as per Your Requirement
  • Other Specific Requirement on Customization
Request Customization Banner

Client Testimonials

“This report is really well done and we really appreciate it! Again, I may have questions as we dig in deeper. Thanks again for some really good work.”

- U.S.-based biotechnology company focussing on treatment of chronic pain.

“Kudos to your team. Thank you very much for your support and agility to answer our questions.”

- Europe-based provider of solutions to automate data centre operations.

“We appreciate you and your team taking out time to share the report and data file with us, and we are grateful for the flexibility provided to modify the document as per request. This does help us in our business decision making. We would be pleased to work with you again, and hope to continue our business relationship long into the future.”

- India-based manufacturer of industrial and specialty intermediates with a strong global presence.

“I want to first congratulate you on the great work done on the Medical Platforms project. Thank you so much for all your efforts.”

- One of the largest cosmetics company in the world.

“Thank you very much. I really appreciate the work your team has done. I feel very comfortable recommending your services to some of the other startups that I’m working with, and will likely establish a good long partnership with you.”

- U.S. based startup operating in the cultivated meat market.

“We received the below report on the U.S. market from you. We were very satisfied with the report.”

- Global hearing aids manufacturer.

“I just finished my first pass-through of the report. Great work! Thank you!”

- U.S. based solar racking solutions provider.

“Thanks again for the great work on our last partnership. We are ramping up a new project to understand the imaging and imaging service and distribution market in the U.S.”

- World’s leading advisory firm.

“We feel positive about the results. Based on the presented results, we will do strategic review of this new information and might commission a detailed study on some of the modules included in the report after end of the year. Overall we are very satisfied and please pass on the praise to the team. Thank you for the co-operation!”

- Germany based machine construction company.

“Thank you very much for the very good report. I have another requirement on cutting tools, paper crafts and decorative items.”

- Japanese manufacturing company of stationery products.

“We are happy with the professionalism of your in-house research team as well as the quality of your research reports. Looking forward to work together on similar projects”

- One of the Leading Food Companies in Germany

“We appreciate the teamwork and efficiency for such an exhaustive and comprehensive report. The data offered to us was exactly what we were looking for. Thank you!”

- Intuitive Surgical

“I recommend Fortune Business Insights for their honesty and flexibility. Not only that they were very responsive and dealt with all my questions very quickly but they also responded honestly and flexibly to the detailed requests from us in preparing the research report. We value them as a research company worthy of building long-term relationships.”

- Major Food Company in Japan

“Well done Fortune Business Insights! The report covered all the points and was very detailed. Looking forward to work together in the future”

- Ziering Medical

“It has been a delightful experience working with you guys. Thank you Fortune Business Insights for your efforts and prompt response”

- Major Manufacturer of Precision Machine Parts in India

“I had a great experience working with Fortune Business Insights. The report was very accurate and as per my requirements. Very satisfied with the overall report as it has helped me to build strategies for my business”

- Hewlett-Packard

“This is regarding the recent report I bought from Fortune Business insights. Remarkable job and great efforts by your research team. I would also like to thank the back end team for offering a continuous support and stitching together a report that is so comprehensive and exhaustive”

- Global Management Consulting Firm

“Please pass on our sincere thanks to the whole team at Fortune Business Insights. This is a very good piece of work and will be very helpful to us going forward. We know where we will be getting business intelligence from in the future.”

- UK-based Start-up in the Medical Devices Sector

“Thank you for sending the market report and data. It looks quite comprehensive and the data is exactly what I was looking for. I appreciate the timeliness and responsiveness of you and your team.”

- One of the Largest Companies in the Defence Industry
We use cookies to enhance your experience. By continuing to visit this site you agree to our use of cookies . Privacy.
X